イリノイ州における骨髄異形成症候群の臨床試験
イリノイ州内の拠点で、骨髄異形成症候群に関する16件の研究が参加者を募集しています。
イリノイ州内の都市
公式研究テキスト（英語）
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Illinois CancerCare-Carthage, Carthage
- 他40件
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06577441Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- University of Chicago Comprehensive Cancer Center, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06484062MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- OSF Saint Joseph Medical Center, Bloomington
- 他54件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Orchard Healthcare Research Inc. (OHR) - Skokie, Skokie
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT07422480Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- University of Chicago, Duchossois Center for Advanced Medicine (DCAM), Chicago
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06465953The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- 他6件
被験者募集中第1/2相
22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- ILCC. Illinois Cancer Centers, Peoria
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/21更新 · NCT06499285Mosaic Trial for Stem Cell Transplant Recipients
- Northwestern University Feinberg School of Medicine, Chicago
被験者募集中
18歳以上 · 全性別 · 2026/08/03更新 · NCT06960993Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Research Site, Decatur
被験者募集中第1/2相
16歳以上 · 全性別 · 2026/07/20更新 · NCT07155226Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
- University of Illinois Cancer Center, Chicago
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/06/26更新 · NCT06802315A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- Northwestern University, Chicago
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/13更新 · NCT05732103A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Northwestern, Chicago
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/03/24更新 · NCT04988555Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Ann & Robert H Lurie Children's Hospital of Chicago, Chicago
被験者募集中第1相
1歳〜40歳 · 全性別 · 2026/03/12更新 · NCT05292664Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
- University of Chicago Comprehensive Cancer Center, Chicago
被験者募集中
18歳以上 · 全性別 · 2026/02/20更新 · NCT05745285SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/24更新 · NCT06501196ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。